Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-08-19FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TECVAYLI (teclistamab-cqyv) from Janssen Biotech, Inc., resulting in an updated label that expan…
-
FDA approval · 2025-08-19FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for TALVEY (talquetamab) from Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss
This clinical trial update reports the development and pilot testing of a new magnetic resonance imaging protocol to quantify multiple myelo…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Study of ODX (OsteoDex) in Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for ODX (OsteoDex) in multiple myeloma, a Phase 1/2 study currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease [Phase 2]
A Phase 2 clinical trial evaluating the SVRd regimen for newly diagnosed multiple myeloma with extramedullary disease is currently recruitin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program [NA]
This is a clinical trial update for a screening and patient navigation program aimed at early detection of multiple myeloma and related diso…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant [Phase 1]
Phase 1 trial evaluating a combination of ibrutinib, lenalidomide, and dexamethasone in multiple myeloma patients ineligible for transplant;…
-
CLINICAL_TRIALS other · 2025-08-17Clinical Trial Update: A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
A prospective clinical trial compares DRd (daratumumab, lenalidomide, dexamethasone) with VRd-lite (bortezomib, lenalidomide, dexamethasone)…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.
This clinical trial update assesses the effects of daratumumab-containing induction on stem cell mobilization, collection, and engraftment i…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating pharmacokinetics, efficacy and safety of subcutaneous CT-P44 vs Darzalex Faspro in combination with lenalidomide …
-
CLINICAL_TRIALS withdrawal · 2025-08-15Clinical Trial Update: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]
A Phase 3 trial comparing talquetamab to belantamab mafodotin in relapsed/refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]
This Phase 1 trial evaluates YTS104 cell injections for relapsed or refractory multiple myeloma and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating an anti-CD38 antibody-drug conjugate for relapsed or refractory multiple myeloma is currently recruiti…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation [NA]
This clinical trial update covers an ongoing study evaluating chaplain-delivered compassion meditation to improve spiritual care for patient…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating venetoclax with daratumumab and dexamethasone, with or without bortezomib, in relapsed or refractory multi…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: IMMUNOPLANT for Newly Diagnosed Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating IMMUNOPLANT for newly diagnosed multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: A Study of Real Life Treatment for Multiple Myeloma (MM)
A real-life treatment study for multiple myeloma sponsored by Takeda is listed as active but not recruiting.
-
CLINICAL_TRIALS other · 2025-08-14Clinical Trial Update: Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease [NA]
An ongoing clinical trial is evaluating Aponermin as a bridging therapy before CAR-T cell infusion for relapsed/refractory multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2025-08-13Clinical Trial Update: Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs [Phase 3]
Phase 3 trial evaluating apixaban for prevention of venous thromboembolism in patients with multiple myeloma treated with IMiDs has complete…
-
CLINICAL_TRIALS trial_result · 2025-08-13Clinical Trial Update: RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial update for RN1201 injection in relapsed/refractory CD19+/BCMA+ hematologic malignancies, currently not recruiting.
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma [Phase 1]
Phase 1 trial of RN1201 Injection in newly diagnosed high-risk cytogenetic multiple myeloma patients who are ineligible or unwilling to unde…
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara [Phase 2]
Phase 2 trial update comparing Daratumumab-bortezomib-dexamethasone (Dara-VCd) against bortezomib-thalidomide-dexamethasone (VTd), followed …
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma [NA]
A clinical trial evaluating the effects of early palliative care integration in patients with newly diagnosed multiple myeloma has completed…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. [Phase 2]
Phase 2 trial update evaluating intensified treatment with carfilzomib in multiple myeloma patients who remain PET-positive after first-line…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan [Phase 1]
This Phase 1 clinical trial update describes ABBV-383 (Etentamig) being studied in adults with relapsed/refractory multiple myeloma in Japan…